Sounds of Science Charles River

What if we could replace mouse model control groups with a virtual equivalent? What would that mean for drug development in terms of cost, time, and animal model reduction? To answer, I am joined by Charles River associate director Laura Lotfi and Guillemette Duchateau-Nguyen from F. Hoffmann-La Roche Ltd, Pharmaceutical Sciences - Roche Innovation Center Basel. Listen now to learn how close we are to replacing some physical models with 1's and 0's.

Alex Sargent, Director of Process Development at Charles River in our Cell and Gene Therapy department, joins me to discuss the work he and his partner put into developing an algorithm to make his job faster and easier. How can you train a computer to accurately sift through the mountains of data generated in drug development? Listen now to find out!

There have been many articles recently about cellular agriculture, or lab-grown meat products. But what happens when a company takes a practical approach to this science fiction concept? Joining me are Charles River's Steven Miklasz from our Biologics Testing Solutions team; and Ramsey Foty, Scientific Director for Fork & Good, a cultivated meat company, to discuss how the sausage is made!

This month I am joined by Benjamin Oakes, scientist, entrepreneur, and co-founder of Scribe Therapeutics. He studied at UC Berkeley, working in the Doudna Lab and Savage Lab during the earliest days of CRISPR. We discuss his personal vision for the future of CRISPR, encouraging advances in the field, and the first ever drug approval for a CRISPR based therapy. 

Norm Wainwright and Foster Jordan have been immersed in the field of limulus amebocyte lysate (LAL) testing for decades, and have seen the progress and refinement of this crucial safety test. With the 20th anniversary of Charles River's Endosafe Cartridge and the recent introduction of recombinant alternatives, we look back at the past and future of endotoxin testing.

I am joined by four experts in their field to discuss what will be hot in rare diseases, drug discovery, artificial intelligence, and animal models in 2024.